DOP2009000236A - Anticuerpos de union a antigenos multiples - Google Patents

Anticuerpos de union a antigenos multiples

Info

Publication number
DOP2009000236A
DOP2009000236A DO2009000236A DO2009000236A DOP2009000236A DO P2009000236 A DOP2009000236 A DO P2009000236A DO 2009000236 A DO2009000236 A DO 2009000236A DO 2009000236 A DO2009000236 A DO 2009000236A DO P2009000236 A DOP2009000236 A DO P2009000236A
Authority
DO
Dominican Republic
Prior art keywords
union
antibodies
multiple antigens
gro
antibody
Prior art date
Application number
DO2009000236A
Other languages
English (en)
Inventor
Eric Dobrzynski
Alexis Paul Godillot
Zdenka Ludmila Jonak
John R White
Stephanie Jane Clegg
Jonathan H Ellis
Volker Germaschewski
Alan P Lewis
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of DOP2009000236A publication Critical patent/DOP2009000236A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)

Abstract

La presente invención se refiere a un anticuerpo que tiene multiples especificidades. En particular, el anticuerpo de la presente invención se une (o presenta reacción cruzada) con la IL-8 humana, Gro-alfa, Gro-beta, Gro-gamma y ENA-78.
DO2009000236A 2007-04-17 2009-10-08 Anticuerpos de union a antigenos multiples DOP2009000236A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91222907P 2007-04-17 2007-04-17
US4413208P 2008-04-11 2008-04-11

Publications (1)

Publication Number Publication Date
DOP2009000236A true DOP2009000236A (es) 2009-11-15

Family

ID=39872910

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000236A DOP2009000236A (es) 2007-04-17 2009-10-08 Anticuerpos de union a antigenos multiples

Country Status (30)

Country Link
US (3) US8496932B2 (es)
EP (1) EP2146745B1 (es)
JP (1) JP5441885B2 (es)
KR (1) KR101560841B1 (es)
CN (1) CN101687035B (es)
AU (1) AU2008243049B2 (es)
BR (1) BRPI0810250A8 (es)
CA (1) CA2684626C (es)
CL (1) CL2008001071A1 (es)
CO (1) CO6251323A2 (es)
CR (1) CR11116A (es)
CY (1) CY1116671T1 (es)
DK (1) DK2146745T3 (es)
DO (1) DOP2009000236A (es)
EA (1) EA024621B1 (es)
ES (1) ES2547475T3 (es)
HK (1) HK1136970A1 (es)
HR (1) HRP20150937T1 (es)
HU (1) HUE027584T2 (es)
IL (1) IL201440A (es)
MA (1) MA31310B1 (es)
MX (1) MX2009011153A (es)
MY (1) MY150525A (es)
NZ (1) NZ580239A (es)
PE (1) PE20090302A1 (es)
PL (1) PL2146745T3 (es)
PT (1) PT2146745E (es)
SI (1) SI2146745T1 (es)
TW (1) TWI473815B (es)
WO (1) WO2008130969A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
CA2783563A1 (en) 2009-12-07 2011-06-16 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
CA2789416A1 (en) * 2010-02-09 2011-08-18 Glaxosmithkline Llc Novel uses
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP6211597B2 (ja) * 2012-05-01 2017-10-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規抗体
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
AU2014248636B2 (en) 2013-03-12 2017-03-30 Decimmune Therapeutics, Inc. Humanized anti-N2 antibodies
JO3580B1 (ar) 2013-03-15 2020-07-05 Lilly Co Eli أجسام مضادة لكيموكين elr+ cxc شامل
US9290570B2 (en) 2013-03-15 2016-03-22 Eli Lilly And Company Pan-ELR+ CXC Chemokine Antibodies
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
EP2796875B8 (en) * 2013-04-23 2020-11-25 Albert-Ludwigs-Universität Freiburg Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis
KR20160021125A (ko) * 2013-05-17 2016-02-24 쌩뜨레 나티오날 데 라 르세르쉬 생띠끄 (씨. 엔. 알. 에스) 항-cxcl1, cxcl7 및 cxcl8 항체 및 이들의 용도
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2019036605A2 (en) * 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
MX2020009296A (es) 2018-03-15 2020-11-13 Chugai Pharmaceutical Co Ltd Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
AU2019239568A1 (en) * 2018-03-23 2020-09-17 Board Of Regents, The University Of Texas System Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor
CA3092695A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Human pd-l2 antibodies and methods of use therefor
US11827709B2 (en) * 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates
TW202206457A (zh) * 2020-04-24 2022-02-16 美商美國禮來大藥廠 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
US20220080044A1 (en) * 2020-09-14 2022-03-17 National Yang-Ming University Method for preventing or treating peripheral arterial occlusive disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE913192A1 (en) * 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
US6448379B1 (en) * 1993-09-14 2002-09-10 Chiron Corporation IL8 inhibitors
JP4423680B2 (ja) * 1995-06-07 2010-03-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄｒ−グラフト化抗組織因子抗体及びその使用
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
AR030753A1 (es) * 2000-09-25 2003-09-03 Smithkline Beecham Corp Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
CN1547590A (zh) * 2000-10-13 2004-11-17 ¸ 人源化抗-LT-β-R抗体
EP1414860B1 (en) 2001-04-26 2009-12-30 Dako Denmark A/S Anti-glycated hemoglobin pan-specific monoclonal antibody
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
AU2003299641C1 (en) 2002-12-16 2016-06-02 Cormorant Pharmaceuticals Ab Human monoclonal antibodies against interleukin 8 (IL-8)
JPWO2004060919A1 (ja) * 2002-12-26 2006-05-11 中外製薬株式会社 ヘテロ受容体に対するアゴニスト抗体
EP1610818A4 (en) * 2004-03-03 2007-09-19 Millennium Pharm Inc MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US20070014720A1 (en) * 2005-06-02 2007-01-18 Gadi Gazit-Bornstein Antibodies directed to CD20 and uses thereof
ES2452115T3 (es) * 2005-06-17 2014-03-31 Imclone Llc Un anticuerpo anti-PDGFRalfa para su uso en el tratamiento de cáncer de huesos metastásico
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains

Also Published As

Publication number Publication date
EA024621B1 (ru) 2016-10-31
MA31310B1 (fr) 2010-04-01
BRPI0810250A2 (pt) 2014-10-14
CN101687035B (zh) 2013-06-12
JP2010524469A (ja) 2010-07-22
KR101560841B1 (ko) 2015-11-11
HRP20150937T1 (hr) 2015-10-09
ES2547475T3 (es) 2015-10-06
US20080262203A1 (en) 2008-10-23
CR11116A (es) 2010-03-22
EA200970954A1 (ru) 2010-08-30
TWI473815B (zh) 2015-02-21
WO2008130969A2 (en) 2008-10-30
HUE027584T2 (en) 2016-11-28
PL2146745T3 (pl) 2015-11-30
CY1116671T1 (el) 2017-03-15
EP2146745A4 (en) 2011-11-30
HK1136970A1 (en) 2010-07-16
PT2146745E (pt) 2015-10-14
US20110229475A1 (en) 2011-09-22
IL201440A0 (en) 2010-06-16
PE20090302A1 (es) 2009-04-03
US8496932B2 (en) 2013-07-30
IL201440A (en) 2016-08-31
EP2146745B1 (en) 2015-06-17
EP2146745A2 (en) 2010-01-27
SI2146745T1 (sl) 2015-10-30
BRPI0810250A8 (pt) 2017-02-21
AU2008243049A1 (en) 2008-10-30
JP5441885B2 (ja) 2014-03-12
MX2009011153A (es) 2009-10-30
CA2684626C (en) 2014-11-04
CA2684626A1 (en) 2008-10-30
CN101687035A (zh) 2010-03-31
DK2146745T3 (en) 2015-09-14
AU2008243049B2 (en) 2011-04-21
US20140010807A1 (en) 2014-01-09
TW200906855A (en) 2009-02-16
NZ580239A (en) 2012-07-27
WO2008130969A3 (en) 2008-12-18
CL2008001071A1 (es) 2009-05-22
CO6251323A2 (es) 2011-02-21
US8828384B2 (en) 2014-09-09
MY150525A (en) 2014-01-30
KR20100020946A (ko) 2010-02-23

Similar Documents

Publication Publication Date Title
DOP2009000236A (es) Anticuerpos de union a antigenos multiples
CL2011002306A1 (es) Anticuerpo o un fragmento de union a antigeno del mismo que se une especificamente a la integrina heterodimero alfa4beta7; y composicion que lo comprende.
CR11298A (es) Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
ECSP14013307A (es) Genzyme corporation
PE20141995A1 (es) Moleculas que son anticuerpos con especificidad por ox 40 humano
CR20120127A (es) Anticuerpos monoclonales
CL2012000254A1 (es) Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión.
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
CL2008003782A1 (es) Anticuerpo bivalente bioespecifico que comprende la cadena ligera y pesada de un anticuerpo que se une a un primer antigeno donde el dominio ch3 se reemplaza por ch1, y la cadena ligera y pesada de un anticuerpo que se une a un segundo antigeno, en el que el dominio ch3 esta reemplazado por cl; metodo de preparacion; y composicion.
CR20140585A (es) Proteinas de union a antigeno st2
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
PE20121249A1 (es) Inmunoglobulinas con dominio variable dual
CR20110238A (es) Anticuerpos muc1*
TR201808535T4 (tr) İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü.
CL2011002380A1 (es) Anticuerpo multiespecifico que comprende un anticuerpo de longitud completa que se une especificamente a un primer antigeno y uno o mas fragmentos fab de cadena sencilla que se unen a uno o mas antigenos, acido nucleico que lo codifica; y composicion farmaceutica que lo comprende.
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
UY33983A (es) Proteínas de Unión de Tipo Anticuerpo con Región Variable Dual que Tienen Orientación de la Región de Unión con Entrecruzamiento.
GT200900167A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano.
PE20071312A1 (es) Anticuerpos contra il-22 humana
NZ701444A (en) Antibodies to matrix metalloproteinase 9